Cargando…

Safety and effective use of landiolol in the ICU

Supplemental landiolol administration (20 or 40 μg kg(-1) min(-1)) effectively diminished harmful hemodynamic changes during bronchoscopic endotracheal suctioning compared to normal saline. However, inappropriate use of landiolol (i.e., failure of evaluating factors that influence hemodynamic change...

Descripción completa

Detalles Bibliográficos
Autores principales: Hifumi, Toru, Kato, Hiroshi, Koido, Yuichi, Kawakita, Kenya, Kuroda, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267602/
https://www.ncbi.nlm.nih.gov/pubmed/25520832
http://dx.doi.org/10.1186/2052-0492-2-16
Descripción
Sumario:Supplemental landiolol administration (20 or 40 μg kg(-1) min(-1)) effectively diminished harmful hemodynamic changes during bronchoscopic endotracheal suctioning compared to normal saline. However, inappropriate use of landiolol (i.e., failure of evaluating factors that influence hemodynamic changes) may iatrogenically further complicate pathophysiology, and relatively higher doses of landiolol may be dangerous. We recommend that landiolol should not be routinely used to control cardiovascular responses during bronchoscopic endotracheal suctioning in the intensive care unit. Careful evaluation of factors influencing hemodynamic changes and close monitoring of the patient are mandatory following landiolol administration. Furthermore, a lower initiation dose is recommended.